Message from the CEO

MBL was founded in 1969 as Japan's first antibody manufacturer. Since then, the company continued to pursue the development of innovative diagnostic technologies, guided by the mission of protecting the healthy lives of people. Step by step, MBL has built a solid foundation on this principle. We believe that the diseases no one has yet confronted are precisely the ones worth challenging. With this conviction, we take pride in our contribution to the advancement of medicine through the development of diagnostic reagents and stand by the hopes of those who suffer.

In the 1970s, we began developing diagnostic reagents for autoimmune diseases, a field in which we continue to hold a leading position today. Building on that foundation, we also launched Japan's first companion diagnostic (CDx) and expanded into genetic diagnostics by steadily taking on new challenges to meet the evolving needs of the healthcare market.

In October 2025, we became a wholly owned subsidiary of Tokuyama Corporation, a company that has long supported society through the power of chemistry. As the core of the Tokuyama Group's life science business, we will accelerate the development of innovative diagnostic reagents.

For those who are ill, not knowing the cause can be very frightening. Diagnostic reagents represent the first step in treatment and can become the source of hope for patients. Regardless of the size of the patient population, MBL will continue to take on new challenges for all those waiting for the chance to begin treatment.

CEO
Hiroki Ito